6 news items
Connecting the Dots of ANKTIVA's Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast
IBRX
17 May 24
cells that have specifically been trained to recognize the cancer cells, resulting in activation and proliferation of these killing cells with durable
Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050
BOLD
BVAXF
IBRX
1 May 24
after surgical removal. This shot is designed to train the immune system to recognize and attack specific mutations in cancer cells
Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050
BOLD
BVAXF
IBRX
1 May 24
tumors after surgical removal. This shot is designed to train the immune system to recognize and attack specific mutations in cancer cells
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
IBRX
22 Apr 24
biological properties of dendritic cells, and drives the generation of memory killer T cells that have specifically been trained to recognize the cancer
ImmunityBio Announces Full Accrual Of First Two Phases Of Cancer Vaccine Trial In Participants With Lynch Syndrome And Initiation Of Randomized Controlled Phase Of The Trial
IBRX
21 Feb 24
with precancer and cancer cells. The vaccine combination is studying whether activation of dendritic cells and training the immune system to recognize those
oipfc 4p7yzp7k8d384s7o6tvx7x078
IBRX
21 Feb 24
cells. The vaccine combination is studying whether activation of dendritic cells and training the immune system to recognize those proteins will destroy
- Prev
- 1
- Next